DrugPatentWatch Database Preview
Antares Pharma Inc Company Profile
What is the competitive landscape for ANTARES PHARMA INC, and when can generic versions of ANTARES PHARMA INC drugs launch?
ANTARES PHARMA INC has three approved drugs.
There are sixteen US patents protecting ANTARES PHARMA INC drugs.
There are sixty patent family members on ANTARES PHARMA INC drugs in fourteen countries.
Summary for Antares Pharma Inc
| International Patents: | 60 |
| US Patents: | 16 |
| Tradenames: | 4 |
| Ingredients: | 3 |
| NDAs: | 3 |
| Patent Litigation for Antares Pharma Inc: | See patent lawsuits for Antares Pharma Inc |
Drugs and US Patents for Antares Pharma Inc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Antares Pharma Inc | OTREXUP | methotrexate | SOLUTION;SUBCUTANEOUS | 204824-004 | Oct 11, 2013 | RX | Yes | Yes | 9,421,333 | See Pricing | Y | See Pricing | |||
| Antares Pharma Inc | OTREXUP | methotrexate | SOLUTION;SUBCUTANEOUS | 204824-006 | Mar 24, 2016 | RX | Yes | Yes | 8,480,631 | See Pricing | Y | See Pricing | |||
| Antares Pharma Inc | OTREXUP | methotrexate | SOLUTION;SUBCUTANEOUS | 204824-007 | Mar 24, 2016 | RX | Yes | Yes | 9,629,959 | See Pricing | Y | See Pricing | |||
| Antares Pharma Inc | XYOSTED (AUTOINJECTOR) | testosterone enanthate | SOLUTION;SUBCUTANEOUS | 209863-002 | Sep 28, 2018 | RX | Yes | Yes | RE44847 | See Pricing | Y | See Pricing | |||
| Antares Pharma Inc | OTREXUP | methotrexate | SOLUTION;SUBCUTANEOUS | 204824-005 | Nov 7, 2014 | DISCN | Yes | No | 8,480,631 | See Pricing | Y | See Pricing | |||
| Antares Pharma Inc | OTREXUP | methotrexate | SOLUTION;SUBCUTANEOUS | 204824-002 | Oct 11, 2013 | RX | Yes | Yes | 8,579,865 | See Pricing | Y | See Pricing | |||
| Antares Pharma Inc | OTREXUP | methotrexate | SOLUTION;SUBCUTANEOUS | 204824-003 | Oct 11, 2013 | RX | Yes | Yes | 7,744,582 | See Pricing | Y | See Pricing | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Antares Pharma Inc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Antares Pharma Inc | OTREXUP | methotrexate | SOLUTION;SUBCUTANEOUS | 204824-004 | Oct 11, 2013 | RE44846 | See Pricing |
| Antares Pharma Inc | OTREXUP | methotrexate | SOLUTION;SUBCUTANEOUS | 204824-003 | Oct 11, 2013 | 7,776,015 | See Pricing |
| Antares Pharma Inc | OTREXUP | methotrexate | SOLUTION;SUBCUTANEOUS | 204824-004 | Oct 11, 2013 | 7,776,015 | See Pricing |
| Antares Pharma Inc | OTREXUP | methotrexate | SOLUTION;SUBCUTANEOUS | 204824-007 | Mar 24, 2016 | RE44846 | See Pricing |
| Antares Pharma Inc | OTREXUP | methotrexate | SOLUTION;SUBCUTANEOUS | 204824-006 | Mar 24, 2016 | RE44847 | See Pricing |
| Antares Pharma Inc | OTREXUP | methotrexate | SOLUTION;SUBCUTANEOUS | 204824-004 | Oct 11, 2013 | 7,744,582 | See Pricing |
| Antares Pharma Inc | OTREXUP | methotrexate | SOLUTION;SUBCUTANEOUS | 204824-005 | Nov 7, 2014 | RE44846 | See Pricing |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for Antares Pharma Inc Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Japan | 2015516845 | See Pricing |
| European Patent Office | 3495009 | See Pricing |
| Australia | 5470499 | See Pricing |
| Israel | 184765 | See Pricing |
| South Korea | 20070117543 | See Pricing |
| Japan | 2002522171 | See Pricing |
| Japan | 6457383 | See Pricing |
| >Country | >Patent Number | >Estimated Expiration |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
